News & Updates

Show Multimedia Only
Apremilast improves symptoms, QoL in patients with genital psoriasis

Apremilast improves symptoms, QoL in patients with genital psoriasis

15 Mar 2024 byStephen Padilla

Treatment with apremilast results in a significant reduction in genital psoriasis (G-PsO), as well as improvements in itch, pain, discomfort, redness, and quality of life (QoL), in patients with moderate-to-severe G-PsO who are intolerant to topical therapies, a study has shown.

Apremilast improves symptoms, QoL in patients with genital psoriasis

15 Mar 2024
Alogliptin ups risk of heart failure exacerbation in T2D patients

Alogliptin ups risk of heart failure exacerbation in T2D patients

13 Mar 2024

In type 2 diabetes (T2D) patients with established heart failure (HF), use of alogliptin appears to contribute to an increased risk of HF exacerbation, reveals a study.

Alogliptin ups risk of heart failure exacerbation in T2D patients

13 Mar 2024